A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Poland- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Poland18 clinical trials in Plewiska k. Poznania, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in PolandBadaniaKliniczne.pl(opens in a new tab)
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
Poland
PolandThe busiest research cities in the country
What the registry says about research in the country
Groundbreaking clinical trials focusing on relapsing forms of multiple sclerosis, evaluating novel therapeutic approaches and comparing treatment efficacies. Studies aim to assess new medications against established treatments for better patient outcomes.
Research includes innovative treatments targeting neurological markers and disability progression reduction.
Dedicated research examining Primary Progressive Multiple Sclerosis (PPMS), with trials evaluating higher-dose treatment protocols and their impact on disease progression.
Investigations focus on improving treatment outcomes for progressive forms of MS through innovative therapeutic approaches.
Clinical trials comparing different therapeutic interventions for multiple sclerosis, including established and novel treatments to determine optimal patient care strategies.
Research emphasizes measuring treatment effectiveness through various clinical endpoints and patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.